NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Tenvie Therapeutics

Tenvie Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://tenvie.com/

Last Round

Series A

Jan 8, 2025

Total Funding Raised

$200M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Tenvie Therapeutics is a biotechnology company that develops a platform of small molecule therapies for treating neurological, cardiometabolic, and ophthalmic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

small molecule therapeuticsdrug discoverybiotechnologyclinical-stage biotechprecision medicineneuroinflammationCNS-penetrantNLRP3 inhibitorSARM1 inhibitordrug pipelinecomputational biologybiotech startupdrug developmenttherapeutic assetspreclinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tenvie Therapeutics Comparables

Compare Tenvie Therapeutics with similar companies based on industry and business-model similarity.

Tenvie Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nura Bio
85%
Sironax
84%
Ventus Therapeutics
84%

Tenvie Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 8, 2025

Tenvie Therapeutics Investors

Notable investors and investment history

Tenvie Therapeutics investors
InvestorRounds
ARCH Venture PartnersSeries A
F-Prime CapitalSeries A
ARCH Venture PartnersSeries A
Mubadala CapitalSeries A
F-Prime CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2026

    Grew 17% QoQ, from 42 to 49 employees.

  • Apr 19, 2026

    Monthly visitors increased 68% MoM.

Tenvie Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tenvie Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tenvie Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range49
Year Founded2023
Last FundingJan 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.